statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI (ciltacabtagene...

CARVYKTI (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Latest Ratings for LEGN
 DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsOverweight Jan 2022Morgan StanleyUpgradesEqual-WeightOverweight Jan 2022Morgan StanleyDowngradesOverweightEqual-Weight...

Analyst Ratings For Legend Biotech

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter...

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene...

Legend Biotechs CARVYKTI (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Analysts at Cantor Fitzgerald began coverage on shares of Legend Biotech (NASDAQ:LEGN - Get Free Report) in a report released on Wednesday, MarketBeat.com reports. The firm set an "overweight" rating...

Legend Biotech (NASDAQ:LEGN) Research Coverage Started at Cantor Fitzgerald

HC Wainwright restated their buy rating on shares of Legend Biotech (NASDAQ:LEGN - Free Report) in a research report report published on Monday, Benzinga reports. They currently have a $87.00 target...

Legend Biotech (NASDAQ:LEGN) Stock Rating Reaffirmed by HC Wainwright

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cantor starts Legend Biotech at Overweight on Carvykti expansion

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dar Bioscience (DARE Research Report), Legend Biotech...

Analysts Offer Insights on Healthcare Companies: Dar  Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)

Legend Biotech Corporation (LEGN) has released an update. Legend Biotech USA Inc., a subsidiary of Legend Biotech Corporation, has entered a Master...

Legend Biotech Boosts Drug Production with Novartis

This is a signal that LEGN's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Legend Biotech (LEGN, $56.89) RSI Indicator left the oversold zone on March 27, 2024

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Watchers	629
52-Wk Low	$42.08
52-Wk High	$77.32

Volume	570,321.00
52-Wk High	$77.32
52-Wk Low	$42.08

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.19	--	--	N/A
Q4'23	-$0.33	-$0.40	-20.43%	MISSED
Q3'23	-$0.31	-$0.17	45.18%	BEAT
Q2'23	-$0.36	-$0.57	-57.92%	MISSED
Q1'23	-$0.42	-$0.34	18.55%	BEAT

LEGN Legend Biotech

About

Feed

News

Sentiment

Earnings

Fundamentals